TABLE 4.
Regulation of CHM on TIMPs in TME of murine tumor models.
| TCM herbs and their components | Murine cancer xenograft models | TIMPs | Mechanisms | References |
| PGDN | B16F10 cells induced melanoma | TAMs | To skew TAMs polarity toward the M1 phenotype | Cao Y. et al. (2019) |
| GLT | AOM/DSS-induced colorectal cancer model | TAMs | To reduce TAM production | Sui et al. (2020) |
| RSV | LLC lung cancer model | TAMs | To diminish tumor-associated M2 polarized macrophages | Sun et al. (2017) |
| DNC | 4T1 breast cancer model. | TAMs | To diminish tumor-associated M2 polarized macrophages | Shiri et al. (2015) |
| QRHX | LLC lung cancer model | TAMs | To decrease TAM production | Xu et al. (2017) |
| YPF | LLC-Luc-induced lung cancer model | TAMs | To promote the transformation of M2 phenotype to M1 phenotype | Wang Y. et al. (2019) |
| TR | 4T1 breast cancer model/AOM/DSS-induced colorectal cancer model | TAMs | To skew TAMs polarity toward the M1 phenotype | Li et al. (2020) |
| CT | JC-induced breast cancer model | DCs | To activate DCs to present antigens to T cell | Chang et al. (2011) |
| PPS | TC-1 cervical cancer model | TADCs | To reverse the immature state of TADCs | Wang Y. et al. (2019) |
| PAMB PCPP | 4T1 breast cancer model | DCs | To improve DC immune activity | Chang et al. (2015) |
| SBS | AOM/DSS-induced colorectal cancer model | MDSCs | To block the immunosuppressive activity of MDSCs | Lin et al. (2015) |
| SGJP | 4T1 breast cancer model | MDSCs | To block the immunosuppressive activity of MDSCs | Lu et al. (2017) |
| PA | 4T1 breast cancer model | MDSCs | To decrease the number of MDSCs | Zheng et al. (2018) |
| RSV | LLC lung cancer model | MDSCs | To inhibit the function of MDSCs | Zhao Y. et al. (2018) |
| AP, AS, CS, SD | 4T1 breast cancer model | MDSCs | To diminish the number of Tregs and MDSCs | Yue et al. (2018) |
| KRG | EL-4 thymoma model | MDSCs | To disrupt the function of MDSCs | Jeon et al. (2011) |
| JHD | H22 hepatoma carcinoma model | MDSCs | To inhibit immunosuppressive activity of MDSCs | Xie et al. (2020) |
| ART | 4T1 breast cancer model | MDSCs | To impair the activity of Tregs and MDSCs | Cao Y. et al. (2019) |
| YHD | 4T1 breast cancer model | MDSCs | To inhibit the activity of MDSCs | Mao et al. (2018) |
| ICA | 4T1 breast cancer model | MDSCs | To impair the suppressive activity of MDSCs | Zhou et al. (2011) |
| CA | LM85 osteosarcoma model. | MDSCs | To block the function of MDSCs | Horlad et al. (2013) |
| BYJD | 4T1 breast cancer model | MDSCs | To decrease the number of MDSC | Tian et al. (2020) |
AP, Andrographis paniculata (Burm.f.) Nees; AS, Eleutherococcus senticosus (Rupr. & Maxim.) Maxim.; CS, Camellia sinensis (L.) Kuntze; SD, Scleromitrion diffusum (Willd.) R.J. Wang; ART, artemisinin; BYJD, Bao-Yuan-Jie-Du decoction; CA, corosolic acid; CT, Carthamus tinctorius L.; DC, dendritic cells; DNC, dendrosomal curcumin; GLT, Garcinia livingstonei T. Anderson; ICA, icariin from Epimedium sagittatum (Siebold & Zucc.) Maxim.; JHD, Jianpi Huayu decoction; KRG, Korean red ginseng; MDSCs, myeloid-derived suppressor cells; PA, water extract of pilose antler; PAMB or PCPP, polysaccharide purified from Astragalus mongholicus Bunge or Codonopsis pilosula subsp. pilosula; PGDN, Panax ginseng C. A. Mey.-derived nanoparticles; PPS, Pinellia pedatisecta Schott; QRHX, Qing-Re-Huo-Xue formulae; RSV, resveratrol; SBS, Shen-ling-Bai-zhu San; SGJP, Shu-Gan-Jian-Pi formula; TADC, decoction tumor-associated dendritic cells; TAM, tumor-associated macrophage; TR, triptolide; YHD, Yang-He decoction; YPF, Yu-Ping-Feng.